Group 1 - The core viewpoint of the news is that Sihuan Pharmaceutical (00460.HK) has had its MSCI ESG rating upgraded from BBB to A as of March 13, 2026, indicating an improvement in its ESG performance [1][3]. - The Sina Finance ESG Rating Center offers 14 ESG services, including information, reports, training, and consulting, aimed at helping listed companies promote ESG concepts and enhance their sustainable development performance [1][3]. Group 2 - The Sina Finance ESG Rating Center is the first Chinese professional information and rating aggregation platform for ESG, dedicated to promoting sustainable development and responsible investment, as well as the values of ESG (Environmental, Social, and Governance) [2][4]. - The center aims to establish ESG evaluation standards suitable for China's characteristics and promote the development of ESG investment in the Chinese asset management industry [2][4].
新浪财经ESG：四环医药 MSCI（明晟）ESG评级调升至A